Revenue Analysis
Total and Operating Revenue: CRWD’s operating revenue has shown a growth trend from $692,580,000 in April 2023 to $845,335,000 by January 2024. This increase indicates growing business activities and market acceptance.
Gross Profit: Gross profit has similarly increased, starting from $523,350,000 in April 2023 and reaching $636,763,000 by January 2024. This growth in gross profit surpasses the growth rate of revenue, suggesting improved efficiencies in cost of sales or higher-margin products.
Cost Management
Cost of Revenue: The cost of revenue has steadily increased from $169,230,000 in April 2023 to $208,572,000 by January 2024, in line with revenue growth, indicating stable cost control in direct costs relative to sales.
Operating Expense: Operating expenses have seen a notable increase from $542,806,000 in April 2023 to $607,092,000 by January 2024. Significant components include research and development, and selling, general, and administration expenses which need to be monitored for efficiency.
Total Expenses: Total expenses have been rising, from $712,036,000 in April 2023 to $815,664,000 by January 2024. The expenses growth rate is slightly higher than revenue growth, which might indicate rising operational cost pressures.
Profitability Analysis
EBITDA: EBITDA increased from $41,878,000 in April 2023 to $117,341,000 by January 2024, indicating a strong improvement in operational profitability and earning capacity.
Operating Income: Operating income experienced a significant turnaround, moving from a loss of $19,456,000 in April 2023 to a profit of $29,671,000 by January 2024. This reflects control over operating expenses and an increase in operating efficiency.
Pretax Income and Net Income: Pretax income reflects growth from $4,908,000 in April 2023 to $68,550,000 by January 2024. Net income also improved significantly from $491,000 in April 2023 to $53,699,000 by January 2024, reflecting not just operating improvements but also effective tax and other income management.
Cash Flow Indicators
Reconciled Depreciation: Depreciation costs have increased, pointing to higher capital expenditures, from $30,583,000 in April 2023 to $42,369,000 by January 2024.
Interest Expense: Interest expense remained relatively stable, indicating controlled debt management despite the growing scale of operations.
Taxation
Tax Rate: Tax rates have varied, from a high of 35.2% in July 2023 to 19.9% by January 2024. Lower recent tax rates may indicate better tax planning or changes in taxable income composition.
Tax Provision: Tax provisions have increased in alignment with pretax income, from $4,409,000 in April 2023 to $13,609,000 by January 2024.
Tax Effect of Unusual Items: There has been no significant impact from unusual items on the tax lines, as reflected by constant $0 values.
Shareholder Metrics
Diluted and Basic EPS: Earnings per share (both diluted and basic) have seen improvements, notably from $0.002041 (diluted) in April 2023 to being unreported yet likely higher in January 2024 given the net income increase.
Average Shares: The number of shares used in computation shows consistency, suggesting stable shareholder equity dilution.
Net Income Available to Common Stockholders: Aligns with reported net income figures, thereby providing straightforward shareholder returns information.
Conclusion
Overall, CRWD has demonstrated robust revenue growth, improved profitability, and managed cost expansions effectively. Strategic initiatives seem to be yielding positive outcomes in both operational efficiencies and market positioning. Continued vigilance on costs, especially in R&D and SG&A, alongside optimized tax strategies, remain essential for maintaining financial health and supporting further growth.
Appendices
Supporting data and detailed calculations would include line-by-line breakdowns from reported figures over the period analyzed, income statement reconciliations, and ratio analyses directly derived from the provided financial data.